Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optical PD-L1 Imaging Using Quantitative Fluorescence Endoscopy in Locally Advanced Esophageal Cancer
NCT05450484Phase 1Completed
- Sponsor
- University Medical Center Groningen
- Start
- Apr 2023
- Primary completion
- Nov 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of durvalumab-680LT in esophageal cancer, sponsored by University Medical Center Groningen. Primary endpoints: Heterogeneity of the PD-L1 tumor expression and Incidence of (severe) adverse events. Started Apr 2023; status: completed.
02
Drugs
durvalumab-680LT
03
Conditions
esophageal cancer
Beyond the preview
Go deeper on NCT05450484.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05450484.